AXQ Capital LP Buys Shares of 10,581 Q32 Bio Inc. (NASDAQ:QTTB)

AXQ Capital LP purchased a new position in Q32 Bio Inc. (NASDAQ:QTTB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,581 shares of the company’s stock, valued at approximately $36,000.

Several other large investors have also recently made changes to their positions in QTTB. Point72 Asset Management L.P. acquired a new stake in Q32 Bio during the 3rd quarter worth $3,422,000. FMR LLC boosted its position in Q32 Bio by 137.3% during the third quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after acquiring an additional 246,664 shares during the last quarter. Rhumbline Advisers grew its stake in Q32 Bio by 1,164.3% during the 4th quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock valued at $363,000 after acquiring an additional 97,196 shares in the last quarter. Barclays PLC raised its holdings in Q32 Bio by 105.2% in the 3rd quarter. Barclays PLC now owns 10,443 shares of the company’s stock valued at $465,000 after acquiring an additional 5,353 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Q32 Bio by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 131,768 shares of the company’s stock worth $5,881,000 after purchasing an additional 24,114 shares in the last quarter. 31.32% of the stock is currently owned by hedge funds and other institutional investors.

Q32 Bio Trading Up 5.3 %

NASDAQ QTTB opened at $2.18 on Tuesday. Q32 Bio Inc. has a 12 month low of $1.80 and a 12 month high of $53.79. The stock has a market capitalization of $26.59 million, a P/E ratio of -0.15 and a beta of -0.27. The firm’s 50-day moving average is $2.68 and its two-hundred day moving average is $21.11. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.09. On average, sell-side analysts anticipate that Q32 Bio Inc. will post -12.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on QTTB shares. Leerink Partnrs cut Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $22.00 to $3.00 in a research note on Tuesday, February 11th. Raymond James reiterated an “outperform” rating and set a $22.00 price target (down previously from $90.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Piper Sandler cut shares of Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a research report on Tuesday, February 11th. Finally, Wells Fargo & Company reduced their target price on shares of Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 12th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Q32 Bio has an average rating of “Hold” and a consensus price target of $24.71.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.